Panousis D, Patsouris E, Lagoudianakis E, Pappas A, Kyriakidou V, Voulgaris Z, Xepapadakis G, Manouras A, Athanassiadou A M, Athanassiadou P
Department of Breast Surgery, Iaso General Hospital, Athens, Greece.
Eur J Gynaecol Oncol. 2011;32(2):156-9.
The immunocytochemical expression of topoisomerase II alpha (TOP2A), enhancer of zeste homologue 2 (EZH2) and paxillin has recently gained increasing attention. Although previous studies have commented on the clinical usefulness of these markers, their role remains controversial.
The purpose of the study was to investigate the expression of TOP2A, EZH2 and paxillin in relation to classic prognostic parameters and their significance as prognostic markers in imprints of resected breast carcinomas.
Imprint smears from 55 patients who underwent surgical treatment for primary carcinoma in our department between 2005 and 2006 were studied immunocytochemically with the use of TOP2A, EZH2 and paxillin antibodies.
The expression of TOP2A correlated with higher histologic grade, tumor size and negative PR expression. High intensity staining for EZH2 expression was associated with higher histologic grade, negative ER and PR expression and positive Ki-67 expression. The expression of paxillin showed no correlation with estrogen/progesterone and HER2 expression nor with tumor grade and stage.
Our data indicate that TOP2A and EZH2 expression are related to a more aggressive tumor phenotype. The expression of paxillin failed to correlate with any of the studied clinicopathologic factors. Further studies are needed to verify these results.
拓扑异构酶IIα（TOP2A）、zeste同源物2增强子（EZH2）和桩蛋白的免疫细胞化学表达最近越来越受到关注。尽管先前的研究对这些标志物的临床实用性进行了评论，但其作用仍存在争议。
本研究旨在探讨TOP2A、EZH2和桩蛋白的表达与经典预后参数的关系，以及它们作为切除乳腺癌印片中预后标志物的意义。
对2005年至2006年在我科接受原发性癌手术治疗的55例患者的印片涂片进行免疫细胞化学研究，使用TOP2A、EZH2和桩蛋白抗体。
TOP2A的表达与较高的组织学分级、肿瘤大小和PR阴性表达相关。EZH2表达的高强度染色与较高的组织学分级、ER和PR阴性表达以及Ki-67阳性表达相关。桩蛋白的表达与雌激素/孕激素、HER2表达以及肿瘤分级和分期均无相关性。
我们的数据表明，TOP2A和EZH2的表达与更具侵袭性的肿瘤表型相关。桩蛋白的表达与任何研究的临床病理因素均无相关性。需要进一步研究来验证这些结果。
